Analyzing the ADAURA Trial of Osimertinib in EGFR+ Lung Cancer

January 15, 2021
Tony S.K. Mok, BMSc, MD, FRCPC

Tony S. K. Mok, BMSc, MD, FRCPC, discusses the ADAURA trial of osimertinib in patients with non–small cell lung cancer.

Tony S. K. Mok, BMSc, MD, FRCPC, chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, discusses the ADAURA trial (NCT02511106) of osimertinib (Tagrisso) in patients with non–small cell lung cancer (NSCLC).

Mok says, if there was an Oscar Award for the lung cancer setting in 2020, then it would probably go to the ADAURA trial. The findings for ADAURA were published in the New England Journal of Medicine and reported the efficacy of osimertinib for patients who are EGFR-mutated with resectable NSCLC in the adjuvant setting.

The primary end point was disease-free survival (DFS) in patient with stage II/IIIa disease. The DFS hazard ratio was 0.17. With the DFS and impressive hazard ratio, Mok says there is a reasonable chance that it may translate into an overall survival (OS) benefit.

Mok believes that every patient with resectable EGFR-mutant lung cancer should be informed about the study. The question of whether we should wait for OS data is debatable; if a patient does not know about this potential option, then they don’t have a choice. He wonders what would happen if there is OS benefit years later, but patients had not been informed? This is an important study, and patients should be informed about it, Mok concluded.